ProShares Ultra Bitcoin ETF vs Mesoblast Limited — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.89, while Mesoblast Limited trades at $18.1 (market cap $2.12B). The key difference: Mesoblast Limited is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | MESO | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $64.41 | $20.96 |
52-Week Low | $8.12 | $10.96 |
Market Cap | — | $2.12B |
Enterprise Value | — | $2.13B |
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.01, down 5.16% over 24 hours amid bearish technical signals. The stock shows weak momentum with moving averages indicating a downtrend and oscillators neutral. Recent news highlights concerns over its leveraged ETF structure causing underperformance versus Bitcoin. The company pays small dividends but key valuation and profitability ratios are unavailable.
Outlook remains cautious due to structural decay risks and negative sentiment. Investment opportunity is limited to speculative traders during sustained bull markets, but risks of volatility decay and investor selling pressure outweigh potential gains in the near term.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Trailing returns across standard periods
Latest headlines on both assets
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →